Adma Biologics price target raised to $10 from $8 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Adma Biologics to $10 from $8 and keeps an Overweight rating on the shares. Adma Biologics has consistently beat on quarterly revenues, and it has raised 2024 and 2025 revenue guidance for the third time this year, the analyst tells investors in a research note. The level of credibility is real, and the enthusiasm hasn’t slowed down, the firm says, and Cantor sees a clear path with strong IP/know-how that could equate to $5B-$6B in clear revenue streams over the next decade.